PA
ITRI icon

PharVision Advisers’s Itron ITRI Stock Holding History

PharVision Advisers’s Portfolio ITRI Stock Details ITRI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-7,172
Closed -$666K – 377
2025
Q4 		$666K Buy
7,172
+4,537
+172% +$494K 0.34% 6
2025
Q3 		$328K Buy
+2,635
New +$335K 0.18% 173
2025
Q2 		– Sell
-2,859
Closed -$300K – 355
2025
Q1 		$300K Buy
+2,859
New +$299K 0.42% 93

Other funds holding ITRI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Impax Asset Management Group
Impax Asset Management Group London, United Kingdom $14.3B AUM 19.8% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Amundi
Amundi Paris, France $367B AUM 31.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

PharVision Advisers's ITRI Position: Q1 2026 in Review

PharVision Advisers sold out of Itron (ITRI) in Q1 2026, closing a stake of 7,172 shares — an estimated $666K sold.

PharVision Advisers first reported a position in ITRI in Q1 2025 and held it in 3 quarters. The position peaked at $666K in Q4 2025. 431 funds tracked by Wall St. Rank hold ITRI as of Q1 2026.

  • PharVision Advisers reported no remaining Itron position as of Q1 2026 after selling out during the quarter.
  • PharVision Advisers sold 7,172 Itron shares in Q1 2026, an estimated $666K.
  • PharVision Advisers first reported a position in Itron in Q1 2025 and held it in 3 quarters.
  • PharVision Advisers's Itron position peaked at $666K in Q4 2025.
  • 431 funds tracked by Wall St. Rank held Itron as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.